<DOC>
	<DOC>NCT00507065</DOC>
	<brief_summary>Assess the safety and efficacy of ADDERALL XR compared to placebo in the treatment of adolescents (aged 13-17) with ADHD. Subjects were assigned to one of two cohorts based on weight (&lt;= 75 kg or &gt; 75 kg).</brief_summary>
	<brief_title>Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Males/females 1317 years of age meeting DSMIV criteria for a primary diagnosis of ADHD Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD Known nonresponder to stimulant medication Documented allergy or intolerance to ADDERALL, ADDERALL XR or amphetamines Conduct Disorder, hypertension, history of seizure Tic disorder or Tourette's disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>